Study of Chemoradiotherapy Combined With Cetuximab in Nasopharyngeal Carcinoma
Study of Chemoradiotherapy Combined With Cetuximab in Nasopharyngeal Carcinoma
This is an open, multicenter phase Ⅱ clinical trial. The purpose of this study is to evaluate
 acute toxicity and efficacy of cetuximab (C225) combined with IMRT + neoadjuvant chemotherapy
 in advanced T stage of nasopharyngeal carcinoma. Besides, to figure out the relationship
 between patient outcome and EGFR gene copy number, expression and mutation.
Inclusion Criteria:

 -  Histologic diagnosis of nasopharyngeal carcinoma

 -  Range from 18～69 years old

 -  T3-4，N0-2，M0 (AJCC 2009)

 -  KPS ≥ 80

 -  Nonmetastatic diseases

 -  WBC count ≥ 4×109/L，Hemoglobin ≥ 100g/L， platelet count ≥ 100×109/L

 -  ALT or AST < 1.5×ULN、bilirubin < 1.5×ULN

 -  0Serum creatinine < 1.5×ULN

 Exclusion Criteria:

 -  Distance metastases

 -  Previously treated (surgery，chemotherapy, radiation therapy，EGFR targeted therapy or
 immunotherapy)

 -  Second malignancy within 5 years

 -  Precious therapy with an investigational agent

 -  Uncontrolled seizure disorder or other serious neurologic disease

 -  ≥ Grade Ш allergic reaction to any drug including in this study

 -  Clinically significant cardiac or respiratory disease

 -  Creatinine clearance < 30ml/min

 -  Drug or alcohol addition

 -  Do not have full capacity for civil acts

 -  Severe complication, active infection

 -  Concurrent immunotherapy or hormone therapy for other diseases

 -  Pregnancy or lactation